Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Essstörungen und Adipositas im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Andries A, Frystyk J, Flyvbjerg A, Støving RK (2014) Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 47: 18–23
Brownley KA, Berkman ND, Peat CM et al (2016) Binge-Eating Disorder in adults: a systematic review and meta-analysis. Ann Intern Med 165: 409–420
Dold M, Aigner M, Klabunde M et al (2015) Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom 84: 110–116
Hay P, Chinn D, Forbes D et al (2014) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry 48: 977–1008
Himmerich H, Treasure J (2018) Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 11: 95–108
Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4): 252–260
Himmerich H, Joaquim M, Bentley J et al (2017) Psychopharmacological options for adult patients with anorexia nervosa: the patients’ and carers’ perspectives. CNS Spectr [Epub ahead of print]
Hudson JI, McElroy SL, Ferreira-Cornwell MC et al (2017) Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: A randomized clinical trial. JAMA Psychiatry 74: 903–910
Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 74: 719–728
le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389: 1399–1409
Levinson CA, Rodebaugh TL, Fewell L et al (2015) D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry 76: e787–793
McElroy SL, Hudson JI, Mitchell JE et al (2015) Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 72: 235–246
Yumuk V, Tsigos C, Fried M et al (2015) European Guidelines for Obesity Management in Adults. Obes Facts 8: 402–424
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Himmerich, H., Benkert, O. (2019). Medikamente zur Behandlung von Essstörungen und Adipositas. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)